Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Oct;24(5):479-e114.
doi: 10.1111/vde.12047. Epub 2013 Jul 5.

Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis

Sallie B Cosgrove  1 , Jody A Wren, Dawn M Cleaver, David D Martin, Kelly F Walsh, Jessica A Harfst, Stacey L Follis, Vickie L King, Joseph F Boucher, Michael R Stegemann
Affiliations
Free PMC article
Randomized Controlled Trial

Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis

Sallie B Cosgrove et al. Vet Dermatol. 2013 Oct.
Free PMC article

Abstract

Background: Oclacitinib (Apoquel(®) ) inhibits the function of a variety of pro-inflammatory, pro-allergic and pruritogenic cytokines that are dependent on Janus kinase enzyme activity. Oclacitinib selectively inhibits Janus kinase 1.

Hypothesis/objectives: We aimed to evaluate the safety and efficacy of oclacitinib for the control of pruritus associated with allergic dermatitis in a randomized, double-blinded, placebo-controlled trial.

Methods: Client-owned dogs (n = 436) with moderate to severe owner-assessed pruritus and a presumptive diagnosis of allergic dermatitis were enrolled. Dogs were randomized to either oclacitinib at 0.4-0.6 mg/kg orally twice daily or an excipient-matched placebo. An enhanced 10 cm visual analog scale (VAS) was used by the owners to assess the severity of pruritus from day 0 to 7 and by veterinarians to assess the severity of dermatitis on days 0 and 7. Dogs could remain on the study for 28 days.

Results: Pretreatment owner and veterinary VAS scores were similar for the two treatment groups. Oclacitinib produced a rapid onset of efficacy within 24 h. Mean oclacitinib Owner Pruritus VAS scores were significantly better than placebo scores (P < 0.0001) on each assessment day. Pruritus scores decreased from 7.58 to 2.59 cm following oclacitinib treatment. The day 7 mean oclacitinib Veterinarian Dermatitis VAS scores were also significantly better (P < 0.0001) than placebo scores. Diarrhoea and vomiting were reported with similar frequency in both groups.

Conclusions and clinical importance: In this study, oclacitinib provided rapid, effective and safe control of pruritus associated with allergic dermatitis, with owners and veterinarians noting substantial improvements in pruritus and dermatitis VAS scores.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) Enhanced Owner Pruritus visual analog scale (VAS). (b) Enhanced Veterinarian Dermatitis VAS.
Figure 2
Figure 2
Owner Pruritus VAS score by day of study (day 0, arithmetic mean; days 1–7, least squares mean ± 95% confidence interval).
Figure 3
Figure 3
Veterinarian Dermatitis VAS score by day of study (day 0, arithmetic mean; day 7, least squares mean ± 95% confidence interval).
Figure 4
Figure 4
Dogs achieving a 2 cm Owner Pruritus VAS score reduction each day of the study.
Figure 5
Figure 5
Dogs achieving a ≥50% Owner Pruritus VAS score reduction each day of the study.
See this image and copyright information in PMC

References

    1. VPI®. Pet Insurance website. Top 10 pet medical conditions of 2010. Available at: http://press.petinsurance.com/pressroom/02222011Pet_Conditions_2010.aspx. Accessed Dec 28, 2012.
    1. Hill PB, Lo A, Eden CAN, et al. Survey of the prevalence, diagnosis and treatment of dermatological conditions in small animals in general practice. Vet Rec. 2006;158:533–539. - PubMed
    1. Nuttall T, McKeever PJ, Harvey RG. Pruritic dermatitis. In: Beynon P, editor. A Colour Handbook of Skin Diseases of the Dog and Cat. London: Manson Publishing; 2009. pp. 35–37. 2nd edn.
    1. Olivry T, Bisikova P. A systematic review of randomized controlled trials for prevention or treatment of atopic dermatitis in dogs: 2008–2011 update. Vet Dermatol. 2013;24:97–117. , e25–e26. - PubMed
    1. Bloom P. Nonsteroidal, nonimmunosuppressive therapies for pruritus. Vet Clin North Am: Small Anim Pract. 2013;43:173–187. - PubMed

Publication types

MeSH terms